氨鲁米特和氢化可的松单独及联合使用对睾丸切除术后前列腺癌患者雄激素水平的影响。
The effects of aminoglutethimide and hydrocortisone, alone and combined, on androgen levels in post-orchiectomy prostatic cancer patients.
作者信息
Dowsett M, Shearer R J, Ponder B A, Malone P, Jeffcoate S L
机构信息
Department of Biochemical Endocrinology, Chelsea Hospital for Women, London, UK.
出版信息
Br J Cancer. 1988 Feb;57(2):190-2. doi: 10.1038/bjc.1988.40.
Abstract
Aminoglutethimide has been used in combination with hydrocortisone in patients with advanced prostatic cancer with the rationale that it causes a 'medical adrenalectomy'. Both objective and subjective responses have been recorded. We have examined the effect of AG and HC alone and in combination on plasma androgen levels throughout the day in two studies on 11 such patients. Whilst AG combined with HC led to a significant suppression of both testosterone and androstenedione levels, the suppression with HC alone was significantly greater, indicating that any beneficial clinical effects of AG in these patients is not due to its suppression of adrenal androgen secretion.
摘要
氨鲁米特已与氢化可的松联合用于晚期前列腺癌患者，其理论依据是它会导致“药物性肾上腺切除术”。已记录到客观和主观反应。我们在两项针对11例此类患者的研究中，考察了氨鲁米特（AG）和氢化可的松（HC）单独及联合使用对全天血浆雄激素水平的影响。虽然AG与HC联合使用导致睾酮和雄烯二酮水平显著降低，但单独使用HC时的降低幅度明显更大，这表明AG对这些患者的任何有益临床效果并非源于其对肾上腺雄激素分泌的抑制作用。
相似文献
1
The effects of aminoglutethimide and hydrocortisone, alone and combined, on androgen levels in post-orchiectomy prostatic cancer patients.氨鲁米特和氢化可的松单独及联合使用对睾丸切除术后前列腺癌患者雄激素水平的影响。
Br J Cancer. 1988 Feb;57(2):190-2. doi: 10.1038/bjc.1988.40.
2
Androgen suppression by hydrocortisone without aminoglutethimide in orchiectomised men with prostatic cancer.
Br J Urol. 1987 Mar;59(3):255-7. doi: 10.1111/j.1464-410x.1987.tb04617.x.
3
Adrenal steroid levels in castrated men with prostatic carcinoma treated with aminoglutethimide plus hydrocortisone.
Cancer Res. 1987 Sep 1;47(17):4736-9.
4
Hydrocortisone alone vs hydrocortisone plus aminoglutethimide: a comparison of the endocrine effects in postmenopausal breast cancer.单独使用氢化可的松与氢化可的松加氨鲁米特的比较：绝经后乳腺癌内分泌效应的对比
Eur J Cancer Clin Oncol. 1984 Apr;20(4):463-9. doi: 10.1016/0277-5379(84)90230-x.
5
A comparison of the endocrine effects of low dose aminoglutethimide with and without hydrocortisone in postmenopausal breast cancer patients.低剂量氨鲁米特联合与不联合氢化可的松对绝经后乳腺癌患者内分泌影响的比较。
Br J Cancer. 1985 Oct;52(4):525-9. doi: 10.1038/bjc.1985.223.
6
Response to aminoglutethimide and cortisone acetate in advanced prostatic cancer.晚期前列腺癌对氨鲁米特和醋酸可的松的反应
Br J Cancer. 1984 Dec;50(6):757-63. doi: 10.1038/bjc.1984.253.
7
Endocrine effects of aminoglutethimide plus hydrocortisone versus effects of high dose of hydrocortisone alone in postmenopausal metastatic breast cancer.氨鲁米特加氢化可的松与单独使用高剂量氢化可的松对绝经后转移性乳腺癌的内分泌影响
Eur J Cancer Clin Oncol. 1987 Sep;23(9):1349-56. doi: 10.1016/0277-5379(87)90119-2.
8
Androgen priming and chemotherapy in advanced prostate cancer: evaluation of determinants of clinical outcome.
J Clin Oncol. 1988 Sep;6(9):1456-66. doi: 10.1200/JCO.1988.6.9.1456.
9
Second line endocrine treatment of postmenopausal advanced breast cancer. Preliminary endocrine results of a 5-arm randomized phase II trial of medium vs low dose aminoglutethimide, with or without hydrocortisone vs hydrocortisone alone (EORTC 10861).绝经后晚期乳腺癌的二线内分泌治疗。一项五臂随机II期试验的初步内分泌结果：中剂量与低剂量氨鲁米特对比，加或不加氢化可的松与单用氢化可的松（欧洲癌症研究与治疗组织10861）
J Steroid Biochem Mol Biol. 1990 Dec 20;37(6):1013-9. doi: 10.1016/0960-0760(90)90459-x.
10
Treatment of stage D2 prostatic cancer refractory to or relapsed following castration plus oestrogens. Comparison of aminoglutethimide plus hydrocortisone with medroxyprogesterone acetate plus hydrocortisone.
Br J Urol. 1990 Aug;66(2):196-201. doi: 10.1111/j.1464-410x.1990.tb14903.x.
引用本文的文献
1
Roles for the backdoor pathway of androgen metabolism in prostate cancer response to castration and drug treatment.雄激素代谢的旁路途径在前列腺癌对去势和药物治疗反应中的作用。
Int J Biol Sci. 2014 Jun 3;10(6):596-601. doi: 10.7150/ijbs.8780. eCollection 2014.
2
Docetaxel as a vital option for corticosteroid-refractory prostate cancer.多西他赛是治疗皮质类固醇难治性前列腺癌的重要选择。
Int Urol Nephrol. 2011 Dec;43(4):1081-7. doi: 10.1007/s11255-011-9922-0. Epub 2011 Mar 11.
3
Hormonal impact of the 17alpha-hydroxylase/C(17,20)-lyase inhibitor abiraterone acetate (CB7630) in patients with prostate cancer.17α-羟化酶/C（17,20）-裂解酶抑制剂醋酸阿比特龙（CB7630）对前列腺癌患者的激素影响。
Br J Cancer. 2004 Jun 14;90(12):2317-25. doi: 10.1038/sj.bjc.6601879.
4
Aromatase inhibition in advanced prostatic cancer: preliminary communication.晚期前列腺癌中的芳香化酶抑制：初步交流。
Br J Cancer. 1990 Aug;62(2):275-6. doi: 10.1038/bjc.1990.276.
5
Aromatase inhibition: 4-hydroxyandrostenedione (4-OHA, CGP 32349) in advanced prostatic cancer.芳香化酶抑制作用：4-羟基雄烯二酮（4-OHA，CGP 32349）在晚期前列腺癌中的应用。
Br J Cancer. 1992 Jul;66(1):139-42. doi: 10.1038/bjc.1992.231.
6
Aromatase inhibitors in malignant diseases of aging.芳香化酶抑制剂在衰老相关恶性疾病中的应用
Drugs Aging. 1992 Nov-Dec;2(6):530-45. doi: 10.2165/00002512-199202060-00008.
本文引用的文献
1
Steroid response to therapy in prostatic cancer.
J Urol. 1957 Mar;77(3):485-91. doi: 10.1016/S0022-5347(17)66589-3.
2
Cortisone treatment in advanced carcinoma of the prostate.
J Urol. 1954 Sep;72(3):485-96. doi: 10.1016/S0022-5347(17)67614-6.
3
Aminoglutethimide therapy for advanced carcinoma of the prostate.
Br J Urol. 1982 Oct;54(5):552-5. doi: 10.1111/j.1464-410x.1982.tb13589.x.
4
Preservation of androgen secretion during estrogen suppression with aminoglutethimide in the treatment of metastatic breast carcinoma.在使用氨鲁米特抑制雌激素治疗转移性乳腺癌期间雄激素分泌的保留情况。
J Clin Invest. 1980 Mar;65(3):602-12. doi: 10.1172/JCI109705.
5
Clinical effect of aminoglutethimide, medical adrenalectomy, in treatment of 43 patients with advanced prostatic carcinoma.
Cancer. 1984 Apr 1;53(7):1447-50. doi: 10.1002/1097-0142(19840401)53:7<1447::aid-cncr2820530703>3.0.co;2-g.
6
Suppression of plasma 6-keto-prostaglandin F1 alpha and 13,14-dihydro-15-keto-prostaglandin F2 alpha by aminoglutethimide in advanced breast cancer.氨鲁米特对晚期乳腺癌患者血浆6-酮-前列腺素F1α和13,14-二氢-15-酮-前列腺素F2α的抑制作用
Br J Cancer. 1983 Oct;48(4):595-8. doi: 10.1038/bjc.1983.233.
7
Effects of aminoglutethimide on adrenal steroid secretion.氨鲁米特对肾上腺类固醇分泌的影响。
Clin Endocrinol (Oxf). 1983 Dec;19(6):673-82. doi: 10.1111/j.1365-2265.1983.tb00044.x.
8
Response to aminoglutethimide and cortisone acetate in advanced prostatic cancer.晚期前列腺癌对氨鲁米特和醋酸可的松的反应
Br J Cancer. 1984 Dec;50(6):757-63. doi: 10.1038/bjc.1984.253.
9
Hydrocortisone alone vs hydrocortisone plus aminoglutethimide: a comparison of the endocrine effects in postmenopausal breast cancer.单独使用氢化可的松与氢化可的松加氨鲁米特的比较：绝经后乳腺癌内分泌效应的对比
Eur J Cancer Clin Oncol. 1984 Apr;20(4):463-9. doi: 10.1016/0277-5379(84)90230-x.
10
Endocrine changes associated with relapse in advanced breast cancer patients on aminoglutethimide therapy.接受氨鲁米特治疗的晚期乳腺癌患者复发相关的内分泌变化。
J Clin Endocrinol Metab. 1984 Jan;58(1):99-104. doi: 10.1210/jcem-58-1-99.
Zotero 插件